Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002, 34 (6): 831-837. 10.1086/339042.
Article
PubMed
Google Scholar
Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL: Hepatitis C and progression of HIV disease. JAMA. 2002, 288 (2): 199-206. 10.1001/jama.288.2.199.
Article
PubMed
Google Scholar
Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE: Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995, 74 (4): 212-220. 10.1097/00005792-199507000-00005.
Article
CAS
Google Scholar
Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P: Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003, 17 (12): 1803-1809. 10.1097/00002030-200308150-00009.
Article
PubMed
Google Scholar
Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M: Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis. 2001, 33 (10): 1793-1795. 10.1086/323009.
Article
CAS
PubMed
Google Scholar
Clinical Practice Guidelines EASL: Management of hepatitis C virus infection. J Hepatol. 2014, 60 (2): 392-420.
Article
Google Scholar
Lindahl K, Stahle L, Bruchfeld A, Schvarcz R: High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005, 41 (2): 275-279. 10.1002/hep.20563.
Article
CAS
PubMed
Google Scholar
Rendon AL, Nunez M, Romero M, Barreiro P, Martin-Carbonero L, Garcia-Samaniego J, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V: Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2005, 39 (4): 401-405. 10.1097/01.qai.0000170034.90438.68.
Article
CAS
PubMed
Google Scholar
Crespo M, Pou L, Esteban JI, Falco V, Ribera E, Lopez R, Sauleda S, Curran A, Villar Del Saz S, Feijoo M, Ocana I, Pahissa A: Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther. 2007, 12 (8): 1217-1223.
CAS
PubMed
Google Scholar
Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G: Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2002, 72 (4): 349-361. 10.1067/mcp.2002.127112.
Article
CAS
PubMed
Google Scholar
Glue P: The clinical pharmacology of ribavirin. Semin Liver Dis. 1999, 19 (Suppl 1): 17-24.
CAS
PubMed
Google Scholar
Jen JF, Glue P, Gupta S, Zambas D, Hajian G: Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000, 22 (5): 555-565. 10.1097/00007691-200010000-00010.
Article
CAS
PubMed
Google Scholar
Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C: Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003, 47 (1): 124-129. 10.1128/AAC.47.1.124-129.2003.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wade JR, Snoeck E, Duff F, Lamb M, Jorga K: Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol. 2006, 62 (6): 710-714. 10.1111/j.1365-2125.2006.02704.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bruchfeld A, Lindahl K, Schvarcz R, Stahle L: Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit. 2002, 24 (6): 701-708. 10.1097/00007691-200212000-00004.
Article
CAS
PubMed
Google Scholar
Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH: Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol. 2007, 47 (1): 23-30. 10.1016/j.jhep.2007.01.027.
Article
CAS
PubMed
PubMed Central
Google Scholar
Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, Denis F, Lunel F, Cales P, Lefebvre A, Fauchais AL, Liozon E, Vidal E: Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008, 47 (5): 1453-1461. 10.1002/hep.22217.
Article
CAS
PubMed
Google Scholar
Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Gunthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C: Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother. 2012, 56 (6): 2959-2966. 10.1128/AAC.05424-11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sauvage FL, Stanke-Labesque F, Gagnieu MC, Jourdil JF, Babany G, Marquet P: Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. Ther Drug Monit. 2009, 31 (3): 374-381. 10.1097/FTD.0b013e3181a665e3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Aguilar Marucco D, Gonzalez De Requena D, Bonora S, Tettoni C, Bonasso M, De Blasi T, D'Avolio A, Sciandra M, Siccardi M, Baietto L, Trentini L, Sinicco A, Cariti G, Di Perri G: The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother. 2008, 61 (4): 919-924. 10.1093/jac/dkn013.
Article
CAS
PubMed
Google Scholar
Piedoux S, Monnet E, Piroth L, Montange D, Royer B, Thevenot T, Kantelip JP, Di Martino V, Muret P: Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C. Antivir Ther. 2011, 16 (8): 1317-1326. 10.3851/IMP1920.
Article
CAS
PubMed
Google Scholar
Sulkowski MS, Benhamou Y: Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007, 14 (6): 371-386. 10.1111/j.1365-2893.2006.00816.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Souvignet C, Maynard M, Gagnieu MC, Trepo C: Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?. J Hepatol. 2007, 47 (1): 1-3.
Article
CAS
PubMed
Google Scholar
Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004, 292 (23): 2839-2848. 10.1001/jama.292.23.2839.
Article
CAS
PubMed
Google Scholar
Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los SI, San Joaquin I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, Garcia-Samaniego J, Soriano V: Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007, 23 (8): 972-982. 10.1089/aid.2007.0011.
Article
CAS
PubMed
Google Scholar
Ribavirin - Summary of Product Characteristics - European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000246/WC500048210.pdf (visited February 2014)
Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001, 357 (9252): 280-281. 10.1016/S0140-6736(00)03618-7.
Article
CAS
PubMed
Google Scholar
Moreno A, Quereda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, Antela A, Dronda F, Navas E, Barcena R, Moreno S: High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther. 2004, 9 (1): 133-138.
CAS
PubMed
Google Scholar
Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Brau N, Hatzakis A, Pol S, Rockstroh J: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007, 21 (9): 1073-1089. 10.1097/QAD.0b013e3281084e4d.
Article
PubMed
Google Scholar